Osmetech hoping for fall approval of UTI test

22 July 2001

Osmetech of the UK, a developer of electronic odor sensors, has said ithopes to be granted US approval of its test for urinary tract infections in the fall. The UTI Microbial Analyzer cuts the time to diagnosis of an infection from days to a few minutes, according to the firm, which added that it is hopeful of signing a licensing agreement with a major pharmaceutical group for the product.

Clinical trials of a second Microbial Analyzer, to detect bacterial vaginosis, are due to start imminently, according to Osmetech, which noted that an earlier trial has already shown that the product can match the accuracy of the existing "gold standard" diagnostic test.

Meantime, Osmetech reported a slight reduction in its net loss for the year ended April 30, to L4.3 million ($6.0 million), down from L4.5 million in 2000.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight